MCID: IND002
MIFTS: 41

Indolent Systemic Mastocytosis malady

Categories: Blood diseases, Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Indolent Systemic Mastocytosis

About this section
Sources:
11Disease Ontology, 13DISEASES, 52Orphanet, 66UMLS, 28ICD10, 37MeSH, 43NCIt, 29ICD10 via Orphanet, 67UMLS via Orphanet, 60SNOMED-CT
See all MalaCards sources

Aliases & Descriptions for Indolent Systemic Mastocytosis:

Name: Indolent Systemic Mastocytosis 11 13 52 66
 
Ism 11

Characteristics:

Orphanet epidemiological data:

52
indolent systemic mastocytosis:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:4660
ICD1028 D47.0
MeSH37 D034721
NCIt43 C9286
SNOMED-CT60 397356009, 70910003
Orphanet52 ORPHA98848
ICD10 via Orphanet29 D47.0
UMLS via Orphanet67 C0272203

Summaries for Indolent Systemic Mastocytosis

About this section
MalaCards based summary: Indolent Systemic Mastocytosis, also known as ism, is related to systemic mastocytosis and mastocytosis, and has symptoms including pruritus, abnormality of skin pigmentation and urticaria. An important gene associated with Indolent Systemic Mastocytosis is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are C-MYB transcription factor network and Regulation of KIT signaling. Affiliated tissues include bone, bone marrow and skin, and related mouse phenotype pigmentation.

Related Diseases for Indolent Systemic Mastocytosis

About this section

Diseases related to Indolent Systemic Mastocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 57)
idRelated DiseaseScoreTop Affiliating Genes
1systemic mastocytosis11.1
2mastocytosis10.7
3corneal granular dystrophy10.4KIT, KITLG
4pericoronitis10.4KIT, KITLG
5movement disease10.4KIT, KITLG
6autosomal recessive non-syndromic intellectual disability10.4KIT, KITLG
7nasopharynx carcinoma10.4KIT, KITLG
8relapsing epidemic typhus10.4KIT, PDGFRA
9asrar facharzt haque syndrome10.4KIT, KITLG
10vagina leiomyosarcoma10.3KIT, PDGFRA
11congenital disorder of glycosylation, type iq10.3KIT, PDGFRA
12malignant biphasic mesothelioma10.3KIT, PDGFRA
13lateral medullary syndrome10.3KIT, PDGFRA
14prostate small cell carcinoma10.3KIT, PDGFRA
15pura syndrome10.3KIT, PDGFRA
16mercaptolactate-cysteine disulfiduria10.3KIT, PDGFRA
17epithelioid leiomyosarcoma10.3KIT, PDGFRA
18pancreatic agenesis10.3KIT, PDGFRA
19multiple spinal canal and spinal cord meningioma10.3KIT, KITLG
20t-b+ severe combined immunodeficiency due to cd3delta/cd3epsilon/cd3zeta10.3KIT, PDGFRA
21malignant fibrous histiocytoma of bone10.3KIT, PDGFRA
22multidrug-resistant tuberculosis10.2KIT, PDGFRA
23caroli disease10.2KIT, PDGFRA
24localized osteosarcoma10.2KIT, PDGFRA
25desmoplastic infantile astrocytoma10.2KIT, PDGFRA
26type c thymoma10.2KIT, PDGFRA
27osteoporosis10.1
28prostate cancer, hereditary, x-linked 110.1KIT, KITLG
29angiokeratoma circumscriptum10.1KIT, PDGFRA
30cell type cancer10.1KIT, PDGFRA
31multiple chemical sensitivity10.1CD2, KIT
32fallopian tube adenosarcoma10.1KIT, PDGFRA
33urticaria pigmentosa10.0
34urticaria10.0
35isolated bone marrow mastocytosis10.0
36mastroiacovo de rosa satta syndrome10.0KIT, KITLG, PDGFRA
37cutaneous solitary mastocytoma10.0HDC, KIT, KITLG
38restrictive cardiomyopathy10.0KIT, KITLG, PDGFRA
39loeffler syndrome10.0KIT, KITLG, PDGFRA
40thrombocythemia 310.0KIT, KITLG, PDGFRA
41peroxisome biogenesis disorder 7a10.0KIT, KITLG, PDGFRA
42gallbladder papillomatosis10.0KIT, PDGFRA
43gastrointestinal stromal tumor10.0KIT, KITLG, PDGFRA
44kala-azar 19.9KIT, KITLG, PDGFRA
45lymphoma9.9
46ileocolitis9.9
47diarrhea9.9
48homocystinuria9.8KIT, KITLG
49hemolytic anemia9.7CD2, KIT
50male reproductive system disease9.6CD2, KIT, PDGFRA

Graphical network of the top 20 diseases related to Indolent Systemic Mastocytosis:



Diseases related to indolent systemic mastocytosis

Symptoms for Indolent Systemic Mastocytosis

About this section

Symptoms:

 52 (show all 13)
  • behavioral abnormality
  • pruritus
  • abnormality of skin pigmentation
  • urticaria
  • sudden cardiac death
  • diarrhea
  • nausea and vomiting
  • abdominal pain
  • headache
  • abnormality of the gastric mucosa
  • reduced bone mineral density
  • impaired temperature sensation
  • mastocytosis

HPO human phenotypes related to Indolent Systemic Mastocytosis:

(show all 13)
id Description Frequency HPO Source Accession
1 pruritus hallmark (90%) HP:0000989
2 abnormality of skin pigmentation hallmark (90%) HP:0001000
3 urticaria hallmark (90%) HP:0001025
4 sudden cardiac death hallmark (90%) HP:0001645
5 diarrhea hallmark (90%) HP:0002014
6 nausea and vomiting hallmark (90%) HP:0002017
7 abdominal pain hallmark (90%) HP:0002027
8 migraine hallmark (90%) HP:0002076
9 impaired temperature sensation hallmark (90%) HP:0010829
10 mastocytosis hallmark (90%) HP:0100495
11 behavioral abnormality typical (50%) HP:0000708
12 abnormality of the gastric mucosa occasional (7.5%) HP:0004295
13 reduced bone mineral density occasional (7.5%) HP:0004349

UMLS symptoms related to Indolent Systemic Mastocytosis:


hepatomegaly, welts

Drugs & Therapeutics for Indolent Systemic Mastocytosis

About this section

Drugs for Indolent Systemic Mastocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1StaurosporinePhase 24562996-74-1
2
Vidarabine47524356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
3
Mycophenolic acid91924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
4
Miconazole357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
Fludarabine109221679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
6
Mycophenolate mofetil919128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil

Interventional clinical trials:

idNameStatusNCT IDPhase
1Study on Mastocytosis for Rupatadine TreatmentCompletedNCT01481909Phase 2, Phase 3
2A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With HandicapRecruitingNCT00814073Phase 3
3Treatment of Indolent Systemic Mastocytosis With PA101CompletedNCT02478957Phase 2
4Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
5Midostaurin in Indolent Systemic MastocytosisActive, not recruitingNCT01920204Phase 2
6A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002RecruitingNCT02808793Phase 1
7Patient-Reported Outcome Questionnaire for Systemic MastocytosisRecruitingNCT02380222
8Mast Cell Connect: A Registry for Patients With MastocytosisRecruitingNCT02620254
9Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisRecruitingNCT02441166
10Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesActive, not recruitingNCT00014235

Search NIH Clinical Center for Indolent Systemic Mastocytosis

Genetic Tests for Indolent Systemic Mastocytosis

About this section

Anatomical Context for Indolent Systemic Mastocytosis

About this section

MalaCards organs/tissues related to Indolent Systemic Mastocytosis:

34
Bone, Bone marrow, Skin, Colon

Animal Models for Indolent Systemic Mastocytosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Indolent Systemic Mastocytosis:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2KIT, KITLG, PDGFRA

Publications for Indolent Systemic Mastocytosis

About this section

Articles related to Indolent Systemic Mastocytosis:

(show all 42)
idTitleAuthorsYear
1
Response of patients with indolent systemic mastocytosis to tamoxifen citrate. (26612479)
2016
2
KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. (26622064)
2016
3
The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. (25582384)
2015
4
Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. (26004600)
2015
5
Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. (25515765)
2015
6
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. (26153655)
2015
7
Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea. (26505934)
2015
8
Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. (24439083)
2014
9
Delayed diagnosis of adult indolent systemic mastocytosis. (25386326)
2014
10
MR-based trabecular bone microstructure is not altered in subjects with indolent systemic mastocytosis. (25542754)
2014
11
Indolent systemic mastocytosis in a patient with ileocolitis. (24975749)
2014
12
Endoscopic findings of indolent systemic mastocytosis involving the colon. (25526423)
2014
13
Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. (24985401)
2014
14
Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis. (24162824)
2013
15
Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. (24155887)
2013
16
Indolent systemic mastocytosis limited to the bone: a case report and review of the literature. (23903270)
2013
17
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. (23621866)
2013
18
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. (23587333)
2013
19
Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. (23659595)
2013
20
Prevalence of indolent systemic mastocytosis in a Dutch region. (23219169)
2013
21
Indolent systemic mastocytosis: a case and review of the current available treatment options. (24011312)
2013
22
Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. (23910691)
2013
23
Indolent systemic mastocytosis: is there a reliable radiographic pattern? (22281758)
2012
24
High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. (22229787)
2012
25
Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. (22469616)
2012
26
Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. (22435702)
2012
27
Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases. (21564325)
2012
28
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. (21193416)
2011
29
Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. (21454873)
2011
30
Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. (21143240)
2011
31
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. (21782049)
2011
32
Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. (21208217)
2011
33
Indolent systemic mastocytosis. (20684189)
2010
34
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. (19541349)
2009
35
High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. (18269681)
2008
36
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. (18177694)
2008
37
Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. (18448146)
2008
38
Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes. (16929885)
2006
39
Use of a doula for labor coaching in a patient with indolent systemic mastocytosis in pregnancy. (16449169)
2006
40
Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. (15722637)
2005
41
Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. (12688351)
2003
42
Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. (9440541)
1997

Variations for Indolent Systemic Mastocytosis

About this section

Expression for genes affiliated with Indolent Systemic Mastocytosis

About this section
Search GEO for disease gene expression data for Indolent Systemic Mastocytosis.

Pathways for genes affiliated with Indolent Systemic Mastocytosis

About this section

Pathways related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
19.7KIT, KITLG
29.7KIT, KITLG
39.7KIT, KITLG
49.6KIT, PDGFRA
59.6KIT, PDGFRA
6
Show member pathways
9.2KIT, KITLG, PDGFRA
7
Show member pathways
9.2KIT, KITLG, PDGFRA
89.2KIT, KITLG, PDGFRA
99.2KIT, KITLG, PDGFRA
109.2KIT, KITLG, PDGFRA
11
Show member pathways
9.2KIT, KITLG, PDGFRA
129.1CLEC11A, KITLG, PDGFRA
138.9CD2, KIT, KITLG
148.9CD2, KIT, KITLG
15
Show member pathways
8.8CD2, CLEC11A, KITLG
16
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
17
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
18
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
19
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
20
Show member pathways
7.9CD2, CLEC11A, KIT, KITLG, PDGFRA
21
Show member pathways
7.9CD2, CLEC11A, KIT, KITLG, PDGFRA
22
Show member pathways
7.9CD2, CLEC11A, KIT, KITLG, PDGFRA

GO Terms for genes affiliated with Indolent Systemic Mastocytosis

About this section

Cellular components related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmic side of plasma membraneGO:00098989.3CD2, KIT

Biological processes related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1embryonic hemopoiesisGO:003516210.3KIT, KITLG
2ectopic germ cell programmed cell deathGO:003523410.2KIT, KITLG
3positive regulation of phospholipase C activityGO:001086310.2KIT, PDGFRA
4positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.1KIT, PDGFRA
5ovarian follicle developmentGO:00015419.9KIT, KITLG
6positive regulation of MAP kinase activityGO:00434069.9KIT, KITLG
7positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.9KIT, PDGFRA
8positive regulation of DNA replicationGO:00457409.7KITLG, PDGFRA
9phosphatidylinositol phosphorylationGO:00468549.7KIT, KITLG, PDGFRA
10regulation of phosphatidylinositol 3-kinase signalingGO:00140669.7KIT, KITLG, PDGFRA
11phosphatidylinositol-mediated signalingGO:00480159.6KIT, KITLG, PDGFRA
12cell chemotaxisGO:00603269.6KIT, PDGFRA
13MAPK cascadeGO:00001659.3KIT, KITLG, PDGFRA
14positive regulation of cell proliferationGO:00082848.1CLEC11A, KIT, KITLG, MVD, PDGFRA

Molecular functions related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:00047149.9KIT, PDGFRA
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.7KIT, KITLG, PDGFRA
3Ras guanyl-nucleotide exchange factor activityGO:00050889.5KIT, KITLG, PDGFRA
4protein homodimerization activityGO:00428038.1CD2, KIT, MVD, PDGFRA

Sources for Indolent Systemic Mastocytosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet